Overview
Sign up for MarketBeat Al Aces to gain aces to MarketBeat's ful suite of research tols:Corcept Therapeutics (NASDAQ:CORT - Get Rating) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research note isued on Friday.A number of other equities research analysts have also comented on the stock. Jeferies Financial Group upgraded shares of Corcept Therapeutics from a "hold" rating to a "buy" rating and raised their price objective for the stock from $21.0 to $35.0 in a report on Wednesday, July 27th.
Key Information
HC Wainwright lifted their price target on shares of Corcept Therapeutics from $29.0 to $3.0 and gave the company a "buy" rating in a research note on Thursday, August 4th. Finaly, Truist Financial lowered shares of Corcept Therapeutics to a "hold" rating in a research note on Tuesday, August 9th. One analyst has rated the stock with a hold rating, thre have given a buy rating and one has isued a strong buy rating to the company.
Acording to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $32.0.Corcept Therapeutics Trading Down 10.4 %Shares of CORT traded down $2.97 during mid-day trading on Friday, hiting $25.5. 1,473,543 shares of the company traded hands, compared to its average volume of 7,517. Corcept Therapeutics has a one year low of $15.82 and a one year high of $30.14.
The busines has a 50-day moving average of $26.64 and a 20 day moving average of $24.86. The stock has a market capitalization of $2.74 bilion, a price-to-earnings ratio of 27.18, a PEG ratio of 3.02 and a beta of 0.56. Corcept Therapeutics (NASDAQ:CORT - Get Rating) last anounced its quarterly earnings data on Wednesday, August 3rd.
Summary
The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, mising analysts' consensus estimates of $0.25 by ($0.01). The busines had revenue of $103.39 milion during the quarter, compared to the consensus estimate of $101.5